Key Documents
Philip Grant
Professional Education
-
Doctor of Philosophy, University of California San Francisco
(2000)
Publications
-
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
Grant P,
Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A.
Clin Infect Dis.
2009;
48
(5):
680-2
-
Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.
Grant P,
Zolopa A.
Curr HIV/AIDS Rep.
2009;
6
(2):
63-7
-
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.
Grant PM,
Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR.
J Clin Virol.
2009;
46
(4):
305-8
-
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Grant P,
Zolopa A.
J HIV Ther.
2008;
13
(2):
36-9
-
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Grant P,
Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen C, Harrington R, Kempf D, Zolopa A.
Antimicrob Agents Chemother.
2008;
52
(11):
4050-6